Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01926366 · ClinicalTrials.gov registry record · Phase 1
AZD6423 SAD/MAD Study in Healthy Volunteers
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
NCT01926366: Completed Phase 1 study, sponsored by AstraZeneca.
NCT01926366 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 175 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (192% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01926366, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD6423 in healthy volunteers. The study includes an up to 28-day screening period, an in-house period during which AZD6423 or placebo will be administered IV, and a 4- to 10-day follow-up period after discharge.
Primary Outcome
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG AZD6423
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
What the finished NCT01926366 record still lists
NCT01926366 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (192% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01926366 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01926366 about?
NCT01926366 is a clinical study titled "AZD6423 SAD/MAD Study in Healthy Volunteers". This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD6423 in healthy volunteers. The study includes an up to 28-day screening period, an in-house period during which AZD6423 or placebo will be administered IV, and a 4- to 10-day follow-up ...
What is the current status of trial NCT01926366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2013-09. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01926366?
The interventions under investigation include: Placebo (DRUG), AZD6423 (DRUG).
Who is sponsoring clinical trial NCT01926366?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01926366's enrollment target sits among peer trials
175 319th of 2000 higher than 1,679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia